Table 2.
Treatment effects of LMTM (5 or 15 mg/kg/day) given alone or following chronic pretreatment with rivastigmine (0.1 or 0.5 mg/kg/day) in wild-type and L1 mice.
| - | Effects in Wild-Type Mice | Effects in Line 1 Mice | ||
|---|---|---|---|---|
| LMTM Alone | Rivastigmine + LMTM | LMTM Alone | Rivastigmine + LMTM | |
| ACh release | ↑ | ↓ | ↑ | ↓ |
| Glutamate release | = | n/a | ↑ | n/a |
| SNARE complex | = | = | = | ↓ |
| Synaptophysin | ↑ | ↓ | ↑ | ↓ |
| α-Synuclein | = | = | = | ↓ |
| Mitochondrial complex IV | = | = | ↑ | ↓ |
| Spatial cognition | = | = | ↑ | ↓ |
| ChAT-positive neurons | = | = | ↑ | ↓ |
| Tau labelling | n/a | n/a | ↓ | ↓ |
Note: Arrows indicate scale and direction of change (red arrows signify treatment effects which reached statistical significance, those in black were directional); =, indicates no effect; and n/a signifies that results are not available yet.